- Report
- August 2023
- 91 Pages
Global
From €3500EUR$3,933USD£3,093GBP
- Report
- July 2023
- 87 Pages
Global
From €3500EUR$3,933USD£3,093GBP
- Report
- August 2021
- 114 Pages
Global
From €3200EUR$3,595USD£2,828GBP
- Report
- May 2022
- 80 Pages
Africa
From €3618EUR$3,795USD£3,090GBP
- Report
- March 2024
- 132 Pages
Global
From €906EUR$950USD£773GBP
- Report
- November 2022
- 310 Pages
Global
From €3661EUR$3,840USD£3,126GBP
- Report
- May 2023
- 147 Pages
Global
From €5719EUR$5,999USD£4,884GBP
- Report
- December 2023
- 160 Pages
United States
From €5719EUR$5,999USD£4,884GBP
- Report
- December 2023
- 188 Pages
Asia Pacific
From €5719EUR$5,999USD£4,884GBP
- Report
- October 2023
- 158 Pages
Latin America
From €3336EUR$3,499USD£2,849GBP
- Report
- April 2023
- 147 Pages
Global
From €5719EUR$5,999USD£4,884GBP
- Report
- May 2022
- 108 Pages
Global
From €4052EUR$4,250USD£3,460GBP
- Report
- March 2022
- 124 Pages
Global
From €4290EUR$4,500USD£3,664GBP
- Report
- March 2020
- 117 Pages
Hungary
From €4100EUR$4,300USD£3,501GBP
Live attenuated vaccines are a type of vaccine that use a weakened form of a virus or bacteria to stimulate an immune response. These vaccines are designed to replicate the natural infection process, allowing the body to develop immunity without the risk of serious illness. Live attenuated vaccines are typically administered orally or nasally, and are often used to protect against diseases such as measles, mumps, rubella, and rotavirus.
Live attenuated vaccines are generally considered to be safe and effective, and are often used in combination with other vaccines to provide broader protection. They are also cost-effective, as they require fewer doses than other types of vaccines.
Notable companies in the live attenuated vaccine market include Merck & Co., GlaxoSmithKline, Sanofi Pasteur, Pfizer, and Novartis. Show Less Read more
